Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Biocryst Pharmaceuticals Inc shares valued at $166,563 were sold by Barnes Alane P on Dec 22 ’25. At $7.65 per share, Barnes Alane P sold 21,773 shares. The insider’s holdings dropped to 398,751 shares worth approximately $2.7 million following the completion of this transaction.
Also, Barnes Alane P purchased 21,773 shares, netting a total of over 166,563 in proceeds.
Before that, Barnes Alane P had sold 21,210 shares from its account. In a trade valued at $162,256, the Chief Legal Officer traded Biocryst Pharmaceuticals Inc shares for $7.65 each. Upon closing the transaction, the insider’s holdings decreased to 21,210 shares, worth approximately $2.14 million.
Analysts at Evercore ISI downgraded the stock from ‘”an Outperform”‘ to ‘”an In-line”‘ outlook in a report released in early October. As of April 29, 2025, Cantor Fitzgerald has initiated its “an Overweight” rating for BCRX. Earlier on February 25, 2025, Wedbush initiated its rating. Their recommendation was “an Outperform” for BCRX stock.
Analyzing BCRX Stock Performance
On last trading session, Biocryst Pharmaceuticals Inc [NASDAQ: BCRX] rose 0.44% to $6.78. The stock’s lowest price that day was $6.69, but it reached a high of $6.85 in the same session. During the last five days, there has been a drop of approximately -14.39%. Over the course of the year, Biocryst Pharmaceuticals Inc shares have dropped approximately -14.50%.
Is Biocryst Pharmaceuticals Inc subject to short interest?
Stocks of Biocryst Pharmaceuticals Inc saw a sharp rise in short interest on 2025-12-31 jumping by 1.68 million shares to 39.06 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 37.38 million shares. A jump of 4.3% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 10.48 of the overall float, the days-to-cover ratio (short ratio) jumped to 10.48.
Which companies own the most shares of Biocryst Pharmaceuticals Inc (BCRX)?
In terms of Biocryst Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 15 in the next 12 months, up nearly 122.22% from the previous closing price of $6.75. Analysts anticipate Biocryst Pharmaceuticals Inc stock to reach 25 by 2026, with the lowest price target being 8. In spite of this, 13 analysts ranked Biocryst Pharmaceuticals Inc stock as Buy at the end of 2026. On November 20, 2023, JP Morgan assigned a price target of “an Overweight” to the stock and resumed coverage with a $10.
